- BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration.
- The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025
- The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque psoriasis and psoriatic arthritis resulting in an anticipated value of $47.24 billion by 2029
Joshua E. Phillipson, BiondVax Pharmaceuticals (NASDAQ: BVXV) Director of Communications and Investor Relations, recently presented the company’s corporate presentation to investors attending the LD Micro Main Event hosted by SRAX, Inc. at the Luxe in Los Angeles and online via Sequire Virtual Events platform October 25-27, 2022. The LD Micro Main Event, known as the “Woodstock” of the micro-cap world, has been showcasing the next big names in the space for the last 15 years. Phillipson was provided with 25 minutes on the main stage to offer investors an in-depth look at the company. The video is available at https://me22.sequireevents.com/recording?session_id=c2bc57cd-a925-43b2-8441-9f927a64b4f7 (free registration required).
BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. BiondVax is developing a pipeline of innovative nanosized…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.